Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
NCT03855280
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemophilia B
Interventions
DRUG:
APVO101
Sponsor
Medexus Pharma, Inc.